Longboard Pharmaceuticals
- Country
- 🇺🇸United States
- Ownership
- Public
- Employees
- 50
- Market Cap
- $1.3B
- Introduction
Longboard Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the research and development of medicines for neurological diseases. The company was founded on January 3, 2020 and is headquartered in San Diego, CA.
A Study to Investigate LP352 in Children and Adults With Developmental and Epileptic Encephalopathy (DEE)
- First Posted Date
- 2025-04-03
- Last Posted Date
- 2025-05-13
- Lead Sponsor
- Longboard Pharmaceuticals
- Target Recruit Count
- 324
- Registration Number
- NCT06908226
- Locations
- 🇺🇸
Site Number - USA19, Little Rock, Arkansas, United States
🇺🇸Site Number - USA29, La Jolla, California, United States
🇺🇸Site Number - USA26, Los Angeles, California, United States
A Study to Investigate LP352 in Children and Adults With Developmental and Epileptic Encephalopathies (DEE)
- Conditions
- Developmental and Epileptic Encephalopathy
- Interventions
- Drug: Placebo
- First Posted Date
- 2024-12-05
- Last Posted Date
- 2025-05-13
- Lead Sponsor
- Longboard Pharmaceuticals
- Target Recruit Count
- 320
- Registration Number
- NCT06719141
- Locations
- 🇨🇳
Site Number - CHN 01, Beijing, China
🇫🇷Site Number - FRA 08, Bron, France
🇫🇷Site Number - FRA 04, Lille, France
A Phase 3, Placebo-Controlled Study to Investigate LP352 in Children and Adults With Dravet Syndrome (DS)
- First Posted Date
- 2024-10-28
- Last Posted Date
- 2025-05-13
- Lead Sponsor
- Longboard Pharmaceuticals
- Target Recruit Count
- 160
- Registration Number
- NCT06660394
- Locations
- 🇮🇹
Site Number - ITA08, Verona, Italy
🇫🇷Site Number - FRA08, Bron, France
🇫🇷Site Number - FRA04, Lille, France
Intermediate-Size Expanded Access Protocol (EAP) for LP352
- Conditions
- Dravet SyndromeLennox Gastaut SyndromeDevelopmental and Epileptic Encephalopathies
- First Posted Date
- 2023-11-29
- Last Posted Date
- 2025-01-22
- Lead Sponsor
- Longboard Pharmaceuticals
- Registration Number
- NCT06149663
- Locations
- 🇺🇸
Rancho Research Institute, Downey, California, United States
🇺🇸Washington University School of Medicine, Saint Louis, Missouri, United States
🇺🇸Children's Neuro Consultants of Austin, Austin, Texas, United States
Open-label, Long-term Safety Study of LP352 in Subjects With Developmental and Epileptic Encephalopathy
- Conditions
- Lennox-Gastaut SyndromeDravet SyndromeDevelopmental and Epileptic Encephalopathy
- Interventions
- Drug: LP352, bexicaserin
- First Posted Date
- 2022-11-25
- Last Posted Date
- 2025-01-27
- Lead Sponsor
- Longboard Pharmaceuticals
- Target Recruit Count
- 41
- Registration Number
- NCT05626634
- Locations
- 🇺🇸
Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States
🇺🇸Northeast Regional Epilepsy Group, Staten Island, New York, United States
🇺🇸University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States
Study to Investigate LP352 in Subjects With Developmental and Epileptic Encephalopathies
- Conditions
- Developmental and Epileptic EncephalopathyLennox Gastaut SyndromeDravet Syndrome
- Interventions
- Drug: Placebo
- First Posted Date
- 2022-05-06
- Last Posted Date
- 2024-11-08
- Lead Sponsor
- Longboard Pharmaceuticals
- Target Recruit Count
- 52
- Registration Number
- NCT05364021
- Locations
- 🇺🇸
University of Miami, Miami, Florida, United States
🇺🇸Consultants in Epilepsy and Neurology, Boise, Idaho, United States
🇦🇺Royal Brisbane Women's Hospital, Herston, Queensland, Australia